FRI-338 - Ledipasvir/Sofosbuvir for 12 weeks is safe and effective in adolescents with chronic hepatitis C virus infection and hematological malignancies undergoing chemotherapy

Autor: El-Sayed, M.H., Ebeid, F.S.E.S., Zekri, A.R., Massetto, B., Kersey, K., Osinusi, A., Zhang, F., Brainard, D., Elsayed, W., El-Haddad, A.
Zdroj: In Journal of Hepatology April 2018 68 Supplement 1:S515-S515
Databáze: ScienceDirect
Externí odkaz: